 | | Anno I – Numero 3, Dicembre 2021 | Comitato scientifico editoriale: Saverio Cinieri
Editore: Intermedia, Direttore Responsabile: Mauro Boldrini | | | | Pubblicazioni recenti |
Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery.
Adjuvant radiotherapy (RT) is currently the standard of care for women with early-stage invasive breast cancer (BC) treated with breast conserving surgery (BCS). However, some women may have very low risk of recurrence and could safely be spared RT. This study aimed to identify these women using a molecularly-based approach … Continua a leggere
|
IDFS and DRFS Benefit Found in Adjuvant Chemotherapy for Premenopausal Women With HR+/HER2- Breast Cancer
Premenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer who had 1 to 3 lymph nodes saw a better survival benefit when treated with adjuvaant chemotherapy plus endocrine therapy compared with postmenopausal women, according to updated results from the SWOG S1007 RxPONDER trial (NCT01272037), presented by … Continua a leggere
|
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary lymph-node–negative breast cancer. In women with positive lymph-node disease, the role of the recurrence score with respect to predicting … Continua a leggere
|
Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing
Genomic tests improve accuracy of risk prediction for early breast cancers but these are expensive. This study evaluated the clinical utility of EndoPredict®, in terms of impact on adjuvant therapy recommendations and identification of parameters to guide selective application. Patients with ER-positive, HER2-negative, and early-stage invasive breast cancer were … Continua a leggere
|
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications
Over the last few years, the indication for chemotherapy use in HR+/HER2− early BC has been significantly modified by the introduction of gene-expression profiling. In the adjuvant setting, several gene-expression signatures have been validated to discriminate early stage HR+/HER2− BC with different prognosis and to identify patients … Continua a leggere
| | | | Appuntamenti Aiom |
Avviso a tutti i Soci
A causa del protrarsi dell‘emergenza coronavirus e delle relative disposizioni, si suggerisce di verificare la conferma dei singoli eventi direttamente con gli organizzatori
|
Landscapes in Oncologia 2021
Precision Medicine – Targeted therapy e immunoterapia
FAD, 1 luglio 2021 – 30 giugno 2022
BACK FROM SAN ANTONIO
15a Edizione
Genova, 14 – 15 gennaio 2022 MANAGEMENT DELLE TOSSICITÀ EMERGENTI DA FARMACI INNOVATIVI (SMART)
FAD, 27 gennaio, 24 febbraio, 24 marzo, 28 aprile, 26 maggio, 23 giugno, 7 luglio, 22 settembre, 20 ottobre 2022 12TH MILAN CONGRESS ON INNOVATIVE ANTICANCER THERAPY
Webinar
27 – 28 gennaio 2022
FOCUS SUL CARCINOMA MAMMARIO
Aggiornamenti basati sull’evidenza – XIX Edizione
Udine, 17 – 18 febbraio 2022
EBCC 13TH EUROPEAN BREAST CANCER CONFERENCE
Barcellona, 23 – 25 marzo 2022
| Questi e altri appuntamenti si possono consultare sul sito AIOM: www.aiom.it
|
© 2020 Editore: Intermedia srl Via Malta 12/B Brescia, BS 25124 Italy
tel. 030 226105 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Iscrizione al Registro degli Operatori di Comunicazione N. 4867
Per contattare la redazione e commentare le notizie clicca qui
Per consultare i numeri arretrati della newsletter clicca qui
Ricevi questa email perché sei iscritto alla newsletter AIOM Cancellati
Privacy
Realizzata con il supporto non condizionato di Genomic Health Inc.,
ora parte di Exact Sciences
|
|
|
|
|